Zeo ScientifiX Inc ZEOX
News
-
ZEO ScientifiX Launches First-of-Its-Kind ZEO Xperience, a Three-Day Immersive Regenerative Medicine Experience for Healthcare Professionals
-
ZEO ScientifiX Strengthens South Florida's Growing Biotechnology Ecosystem Through Regenerative Medicine Innovation
-
ZEO ScientifiX Reports Strong Revenue Growth for Three Months and Six Months Ended April 30, 2026
-
ZEO ScientifiX to Host Live Educational Webinar for Healthcare Professionals Exploring the Southeast Regenerative Medicine Revolution
-
ZEO ScientifiX Donates Products to Support Pediatric Burn Reconstruction Mission in Peru
-
ZEO ScientifiX Expands Medical Advisory Board with Leaders in Regenerative and Longevity Medicine
-
ZEO ScientifiX Launches Physician-Led Patient Masterclass Program Following Grassroots Demand in the Southeast
Trading Information
- Previous Close Price
- $1.42
- Day Range
- $1.44–1.44
- 52-Week Range
- $0.97–2.99
- Bid/Ask
- $1.44 / $1.50
- Shares Outstanding
- 7.84M
- Market Cap
- $11.01M
- Volume/Avg
- 2,800 / 6,086
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.40
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 20
- Website
- https://www.organicell.com
Valuation
|
Metric
|
ZEOX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 15.48 |
Price/Sales | 1.40 |
Price/Cash Flow | — |
Price/Earnings
ZEOX
Financial Strength
|
Metric
|
ZEOX
|
|---|---|
Quick Ratio | 0.68 |
Current Ratio | 1.05 |
Interest Coverage | −50.79 |
Quick Ratio
ZEOX
Profitability
|
Metric
|
ZEOX
|
|---|---|
Return on Assets (Normalized) | −26.47% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ZEOX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!qD%Nb | LOCK|ZH## | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?>s?%x | LOCK|scPN | $83B | |||
| argenx SE ADR
ARGX
| LOCK|>%!m&F | LOCK|P< | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|n&!snY!@ | LOCK|jxl^ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!^bJN?J | LOCK|>c! | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&gRMNqv | LOCK|!?^P& | $29B | |||
| Incyte Corp
INCY
| LOCK|TS&M#! | LOCK|NQ | $25B | |||
| Moderna Inc
MRNA
| LOCK|j>h<&& | LOCK|%W | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|d^!L^>? | LOCK|!tk | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|v&?L%&S | LOCK|G$ | $17B |
United States